Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/advs.202101222 http://scihub22266oqcxt.onion/10.1002/advs.202101222 34180141!8420376!34180141     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Sci+(Weinh) 2021 ; 8 (17): e2101222 Nephropedia Template TP {{tp|p=34180141|t=2021. Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 |pdf=|usr=}}{{34180141}} gab.com Text Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 JO: Adv Sci (Weinh) http://www.kidney.de/pget.php?&tw=1&pmid=34180141 #FOAvip COVID-19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD(+) ) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID-19 patients. CMAs include l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate, salt form of l-carnitine. Placebo-controlled, open-label phase 2 study and double-blinded phase 3 clinical trials are conducted to investigate the time of symptom-free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems. Twit Text FOAVip Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 ????Adv Sci (Weinh) http://www.kidney.de/pget.php?&tw=1&pmid=34180141 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34180141 #FOAvip English Wikipedia <ref>{{Cite pmid|34180141}}</ref> Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 #MMPMID34180141 Altay O; Arif M; Li X; Yang H; Aydin M; Alkurt G; Kim W; Akyol D; Zhang C; Dinler-Doganay G; Turkez H; Shoaie S; Nielsen J; Boren J; Olmuscelik O; Doganay L; Uhlen M; Mardinoglu A Adv Sci (Weinh) 2021[Sep]; 8 (17): e2101222 PMID34180141show ga COVID-19 is associated with mitochondrial dysfunction and metabolic abnormalities, including the deficiencies in nicotinamide adenine dinucleotide (NAD(+) ) and glutathione metabolism. Here it is investigated if administration of a mixture of combined metabolic activators (CMAs) consisting of glutathione and NAD+ precursors can restore metabolic function and thus aid the recovery of COVID-19 patients. CMAs include l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate, salt form of l-carnitine. Placebo-controlled, open-label phase 2 study and double-blinded phase 3 clinical trials are conducted to investigate the time of symptom-free recovery on ambulatory patients using CMAs. The results of both studies show that the time to complete recovery is significantly shorter in the CMA group (6.6 vs 9.3 d) in phase 2 and (5.7 vs 9.2 d) in phase 3 trials compared to placebo group. A comprehensive analysis of the plasma metabolome and proteome reveals major metabolic changes. Plasma levels of proteins and metabolites associated with inflammation and antioxidant metabolism are significantly improved in patients treated with CMAs as compared to placebo. The results show that treating patients infected with COVID-19 with CMAs lead to a more rapid symptom-free recovery, suggesting a role for such a therapeutic regime in the treatment of infections leading to respiratory problems. |Adult[MESH] |Aged[MESH] |Antioxidants/metabolism[MESH] |COVID-19/blood/*metabolism[MESH] |Double-Blind Method[MESH] |Female[MESH] |Humans[MESH] |Inflammation/blood/metabolism[MESH] |Male[MESH] |Metabolome/physiology[MESH] |Middle Aged[MESH] |Proteins/metabolism[MESH] |Proteome/metabolism[MESH]Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate(epmc).pdf DeepDyve Pubget Overpricing